Drugs for Aspirin Resistance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 51)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Cilostazol |
Approved, Investigational |
Phase 4 |
|
73963-72-1 |
2754 |
Synonyms:
3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
3,4-dihydro-6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
73963-72-1
89332-50-3
AC1L1EE2
AC-4334
BRD-K67017579-001-04-2
BRD-K67017579-001-05-9
BRD-K67017579-001-07-5
BRD-K67017579-001-13-3
BRN 3632107
BSPBio_002759
C 0737
C045645
C0737_SIGMA
C20H27N5O2
CHEBI:31401
CHEMBL799
CID2754
cilostazol
Cilostazol
Cilostazol (JP15/USAN/INN)
Cilostazol [INN:JAN]
Cilostazole
Cilostazolum
Cilostazolum [INN-Latin]
CL23867
CPD000058428
D01896
DB01166
EU-0100218
HMS1922N15
HMS2093M14
|
KBio3_002259
KBioGR_001184
Lopac0_000218
Lopac-C-0737
LS-142693
MLS000028470
MLS000758281
MLS000759507
MLS001076067
MLS002153891
MolPort-001-758-007
NCGC00015207-01
NCGC00015207-02
NCGC00015207-06
NCGC00015207-10
NCGC00022153-02
NCGC00022153-04
NCGC00022153-05
NCGC00022153-06
NCGC00022153-07
OPC 13013
OPC 21
OPC-13013
OPC-21
Otsuka brand of cilostazol
Pletaal
Pletal
Pletal (TN)
Pletal, Cilostazol
S1294_Selleck
SAM001246734
SAM001247085
SMR000058428
SPBio_001256
SPECTRUM1505230
Spectrum2_001118
Spectrum3_001170
Spectrum4_000772
Spectrum5_001762
TL8005113
Tocris-1692
UNII-N7Z035406B
ZINC01552174
|
|
2 |
|
Dipyridamole |
Approved |
Phase 4 |
|
58-32-2 |
3108 |
Synonyms:
2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine
2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine
2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine
4-26-00-03840 (Beilstein Handbook Reference)
58-32-2
AB00051974
AC-18100
AC1L1F6T
AC1Q7CXU
AC1Q7CXW
AC1Q7CXX
Agilease
AKOS000509426
Anginal
Antistenocardin
apo-Dipyridamole
Apo-Dipyridamole
Apo-Dipyridamole Fc
Apo-Dipyridamole Sc
Apotex brand OF dipyridamole
Apotex Brand of Dipyridamole
Apricor
Ashbourne brand OF dipyridamole
Ashbourne Brand of Dipyridamole
BAS 00818792
Belmac brand OF dipyridamole
Belmac Brand of Dipyridamole
Berlin chemie brand OF dipyridamole
Berlin Chemie Brand of Dipyridamole
Berlin-chemie brand OF dipyridamole
Berlin-Chemie Brand of Dipyridamole
BIM-0050449.0001
Bio-0173
Boehringer ingelheim brand OF dipyridamole
Boehringer Ingelheim Brand of Dipyridamole
BPBio1_000270
BRD-K86301799-001-04-1
BRN 0068373
BSPBio_000244
BSPBio_001554
BSPBio_001924
C24H40N8O4
Cardioflux
Cardoxil
Cardoxin
CAS-58-32-2
Cerebrovase
CHEBI:4653
CHEMBL932
Chilcolan
CID3108
Cleridium
Cléridium
Cleridium 150
Coribon
Coridil
Coronarine
Corosan
Coroxin
CPD000058382
Curantil
Curantyl
D 9766
D00302
D004176
D2274
D9766_SIGMA
DB00975
Dipiridamol
Dipiridamol [INN-Spanish]
Dipyramidole
Dipyridamine
Dipyridamol
dipyridamole
Dipyridamole
Dipyridamole (JP15/USP/INN)
Dipyridamole [USAN:INN:BAN:JAN]
Dipyridamolum
Dipyridamolum [INN-Latin]
Dipyridan
Dipyudamine
DivK1c_000696
Dypyridamol
EINECS 200-374-7
EU-0100464
Gulliostin
HMS1568M06
HMS1791N16
HMS1920I10
HMS1989N16
|
HMS2089N15
HMS2091O18
HMS502C18
IDI1_000696
IPRAD brand OF dipyridamole
IPRAD Brand of Dipyridamole
Iv Persantine
Justpertin
KBio1_000696
KBio2_001484
KBio2_004052
KBio2_006620
KBio3_001144
KBioGR_001123
KBioSS_001484
Kurantil
Lopac0_000464
Lopac-D-9766
LS-66732
Miosen
MLS000028420
MLS001076306
MLS001333724
MolPort-001-792-504
Natyl
NCGC00015385-01
NCGC00015385-02
NCGC00015385-03
NCGC00015385-07
NCGC00015385-15
NCGC00023914-02
NCGC00023914-04
NCGC00023914-05
NCGC00023914-06
NCGC00023914-07
NCGC00023914-08
NCGC00023914-09
NCGC00023914-10
NCGC00023914-11
NCI60_005689
NINDS_000696
novo-Dipiradol
Novo-Dipiradol
Novopharm brand OF dipyridamole
Novopharm Brand of Dipyridamole
NSC 515776
NSC515776
NSC-515776
Peridamol
Permiltin
Permole, Persantine, Dipyridan, Dipyridamole
Persantin
Persantine
Persantine (TN)
Piroan
Prandiol
Prandiol 75
Prestwick_145
Prestwick0_000142
Prestwick1_000142
Prestwick2_000142
Prestwick3_000142
Protangix
RA 8
RA-8
S1867_Selleck
S1895_Selleck
SAM002264609
SMP2_000208
SMR000058382
SPBio_001003
SPBio_002183
Spectrum_001004
SPECTRUM1500259
Spectrum2_000972
Spectrum3_000402
Spectrum4_000522
Spectrum5_000839
Stenocardil
Stenocardiol
Stimolcardio
Tocris-0691
UNII-64ALC7F90C
UPCMLD-DP072
UPCMLD-DP072:001
Usaf ge-12
Usaf Ge-12
WLN: T66 BN DN GN INJ CCN HCN E- AT6NTJ B2Q F2Q& J- AT6NTJ B2Q F2Q
ZINC00643046
|
|
3 |
|
Heparin |
Approved, Investigational |
Phase 4 |
|
9005-49-6 |
46507594 772 |
Synonyms:
101921-26-0
102785-31-9
102-94-3
104521-37-1
11078-24-3
11129-39-8
12656-11-0
37324-73-5
9041-08-1
9045-22-1
9075-96-1
913079-23-9
91449-79-5
AC1L1ROY
ALFA 87-120
ALFA 87-163
ALFA 87-198
ALFA 87-81
ALFA 88-247
Allocinnamic acid
alpha-Heparin
Alpha-Heparin
Ardeparin
Ardeparin sodium
Ariven
Arteven
Bemiparin
Bemiparin sodium
Calcilean
Calciparine
Certoparin
CID8784
cis-.beta.-Carboxystyrene
cis-Cinnamic acid
Clexane
Clivarin
Clivarine
CY 216
Cy 222
Dalteparin
Dalteparin sodium
Depo-Heparin
EINECS 232-681-7
Enoxaparin
Enoxaparin sodium
Eparina
Eparina [DCIT]
Fluxum
FR 860
Fragmin A
Fragmin B
Fragmin IV
Fraxiparin
H 2149
Hed-heparin
Hed-Heparin
Hep Flush Kit in plastic container
Hepalean
heparin
Heparin Cy 216
Heparin CY 216
Heparin Leo
Heparin Lock Flush
Heparin Lock Flush in plastic container
Heparin Lock Flush preservative free
Heparin Lock Flush preservative free in plastic container
Heparin natrium
Heparin sodium
Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 1,000 units in dextrose 5% in plastic container
Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 10,000 units in dextrose 5%
Heparin sodium 10,000 units in dextrose 5% in plastic container
Heparin sodium 10,000 units in sodium chloride 0.45%
Heparin sodium 10,000 units in sodium chloride 0.9%
Heparin sodium 12,500 units in dextrose 5%
Heparin sodium 12,500 units in dextrose 5% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.9%
Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 2,000 units in dextrose 5% in plastic container
Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 20,000 units and dextrose 5% in plastic container
Heparin sodium 20,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units and dextrose 5% in plastic container
Heparin sodium 25,000 units in dextrose 5%
|
Heparin sodium 25,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.9%
Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units in dextrose 5% in plastic container
Heparin sodium 5,000 units in sodium chloride 0.45%
Heparin sodium 5,000 units in sodium chloride 0.9%
Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container
Heparin sodium in plastic container
Heparin sodium preservative Free
Heparin sodium salt
Heparin sulfate
Heparin sulphate
Heparin, sodium salt
Heparina
Heparina [INN-Spanish]
Heparinate
Heparine
Heparine [INN-French]
Heparinic acid
Heparinsodiumsalt
Heparinum
Heparinum [INN-Latin]
Heparinum natricum
Hepathrom
Hepflush-10
Hep-Lock
Hep-Lock U/P
HSDB 3094
Innohep
Inno-Hep
Isocinnamic acid
Kabi 2165
KB 101
Leparan
LHN 1
Lioton 1000
Lipo-hepin
Lipo-Hepin
Liquaemin
Liquaemin Lock Flush
Liquaemin Sodium
Liquaemin sodium preservative free
Liquemin
Logiparin
Low molecular weight heparin sodium
Minolteparin sodium
MolPort-003-760-257
Multiparin
Nadroparin
Nadroparine
Novoheparin
NSC174025
Octaparin
OP 386
OP 622
Pabyrin
Panheprin
Parnaparin
Parnaparin sodium
Parvoparin
Pularin
Reviparin
Reviparin sodium
Ro 11
Sandoparin
Sodium acid heparin
Sodium heparin
Sodium heparinate
Subeparin
Sublingula
Thromboliquine
Tinzaparin
Tinzaparin sodium
Triofiban
Unfractionated heparin
UNII-12M44VTJ7B
UNII-3S182ET3UA
UNII-E47C0NF7LV
UNII-T2410KM04A
UNII-ZZ45AB24CA
Vetren
Vitrum AB
WY 90493RD
|
|
4 |
|
Tirofiban |
Approved |
Phase 4 |
|
144494-65-5 |
60947 |
Synonyms:
(2S)-2-(Butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoate
(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid
(2S)-2-(Butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid
(2S)-2-(Butylsulphonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoate
(2S)-2-(Butylsulphonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid
142373-60-2 (hydrochloride)
144494-65-5
151065-53-1
AC1L1U7O
AC1Q6VFB
AGG
Aggrastat
Agrastat
Agrastat (TN)
BIDD:GT0363
C07965
C22H36N2O5S
Cahill may roberts brand OF tirofiban hydrochloride monohydrate
CHEBI:40602
CHEBI:9605
CHEMBL916
CID60947
D08607
DB00775
HSDB 7323
|
L-700,462
L-700462
LS-173214
Merck brand OF tirofiban hydrochloride monohydrate
Merck frosst brand OF tirofiban hydrochloride monohydrate
Merck sharp and dohme brand OF tirofiban hydrochloride monohydrate
MK-383
MSD Brand OF tirofiban hydrochloride monohydrate
N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine
N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine
N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE
n-(butylsulfonyl)-o-[4-(piperidin-4-yl)butyl]-l-tyrosine
N-(Butylsulphonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine
tirofiban
Tirofiban
Tirofibán
Tirofiban (INN)
Tirofiban [BAN:INN]
Tirofiban [INN:BAN]
Tirofiban hydrochloride
Tirofiban hydrochloride monohydrate
tirofibanum
Tirofibanum
UNII-GGX234SI5H
|
|
5 |
|
Bivalirudin |
Approved, Investigational |
Phase 4 |
|
128270-60-0 |
16129704 |
Synonyms:
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-4-amino-2-[[2-[[2-[[2-[[2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2R)-2-amino-3-cyclohexylpropanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]-4-oxobutanoyl]amino]acetyl]amino]-4-hydroxy-4-oxobutanoyl]amino]-3-cyclohexylpropanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-5-hydroxy-5-oxopentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoic acid
128270-60-0
Angiomax
BG 8967
BG8967
BG-8967
Bivalirudin
Bivalirudin [USAN:BAN:INN]
bivalirudina
Bivalirudina
bivalirudine
bivalirudinum
Bivalirudinum
C074619
|
C9H11NO.C2H6.CH4
CHEBI:59173
DB02351
D-Phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leucine
Hirulog
Hirulog-1
HS-2004
LS-172701
Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen
Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu
Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64)
The Medicines Company brand of bivalirudin
UNII-TN9BEX005G
|
|
6 |
|
Triflusal |
Approved, Investigational |
Phase 4 |
|
322-79-2 |
|
Synonyms:
|
7 |
|
Thrombin |
Approved, Investigational |
Phase 4 |
|
|
|
Synonyms:
coagulation factor II
Thrombin bovine
|
Thrombin, Topical (Bovine)
|
|
8 |
|
Atorvastatin |
Approved |
Phase 4 |
|
134523-00-5 |
60823 |
Synonyms:
(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
(3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
(betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
134523-00-5
134523-03-8
7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID
7-[2-(4-fluoro-PHENYL)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoate
7-[2-(4-fluoro-PHENYL)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoIC ACID
AC-15611
AC1L1TZT
AC1Q1OZQ
AKOS000281127
Anhydrous, atorvastatin calcium
Atogal
Atorlip
Atorpic
atorvastatin
Atorvastatin
Atorvastatin (INN)
Atorvastatin [INN:BAN]
Atorvastatin acid
Atorvastatin calcium
Atorvastatin calcium anhydrous
Atorvastatin calcium hydrate
Atorvastatin calcium trihydrate
Atorvastatin, calcium salt
atorvastatina
Atorvastatina
atorvastatine
Atorvastatine
atorvastatinium
atorvastatinum
Atorvastatinum
atrovastin
BIDD:GT0336
C06834
C33H35FN2O5
|
Calcium anhydrous, atorvastatin
Calcium hydrate, atorvastatin
Calcium salt atorvastatin
Calcium trihydrate, atorvastatin
Calcium, atorvastatin
Cardyl
CCRIS 7159
CHEBI:39548
CHEMBL1487
CI 981
CID60823
D07474
DB01076
Faboxim
Hipolixan
HSDB 7039
Hydrate, atorvastatin calcium
Lipitor
Lipitor (TN)
Lipitor(TM)
Lipotropic
Lipovastatinklonal
Liprimar
Liptonorm
Lowden
LS-136975
MolPort-000-883-773
NCGC00159458-02
nchembio.301-comp8
Normalip
Sincol
Sortis
Sortis (TN)
Sotis
Torvacard
Torvast
Totalip
Tozalip
Trihydrate, atorvastatin calcium
Tulip
UNII-A0JWA85V8F
Vastina
Xanator
Xarator
Xavator
Zurinel
|
|
9 |
|
Nitroglycerin |
Approved, Investigational |
Phase 4 |
|
55-63-0 |
4510 |
Synonyms:
1,2,3-propanetrioltrinitrate
1,2,3-Propanetrioltrinitrate
1,2,3-Propanetrioltrinitric acid
1,2,3-propanetriyl nitrate
1,2,3-Propanetriyl nitrate
1,2,3-Propanetriyl nitric acid
100292-13-5
105469-31-6
55-63-0
80066-48-4
8013-23-8
9010-02-0
AC1L1IBV
Adesitrin
Aldonitrin
Angibid
Anginine
Angiolingual
Angiplex
Anglix
Angonist
Angorin
Anogesic
Aquo-Trimitrosan
BIDD:GT0142
Blasting gelatin
Blasting oil
BRN 1802063
Buccal
Buccard
c0061
C07455
C3H5N3O9
Cardabid
Cardamist
Cardinit
Cardiodisco
CCRIS 4089
Cellegesic
CHEBI:28787
CHEMBL730
Chitamite
CID4510
Colenitral
Cordipatch
Corditrine
Coro-Nitro
CPD-143
D00515
D005996
Dauxona
DB00727
Deponit
Deponit 5
Deponit TTS 10
Deponit TTS 5
Deponit-5
Diafusor
Discotrine
Dynamite
EINECS 200-240-8
Epinitril
Gepan Nitroglicerin
Gilucor nitro
Gilustenon
Glonoin
Glycerin trinitrate
Glycerin trinitric acid
Glycerine trinitrate
Glycerintrinitrate
Glycerol trinitrate
Glycerol trinitric acid
Glycerol, nitrate triester
Glycerol, nitric acid triester
Glyceroli trinitratis
Glyceroltrinitraat
Glyceroltrinitrat
Glyceryl
Glyceryl nitrate
Glyceryl trinitrate
Glyceryl trinitric acid
Glycerylnitrat
Glytrin
GTN
GTN-Pohl
Herwicard
Herzer
HMS2094M15
HSDB 30
IMX-150
Klavikordal
Lenitral
Lentonitrina
LS-7741
MED-2002
Millisrol
Minitram
Minitran
Minitran (TN)
Minitro
Mionitrat
Mi-Trates
MQX-503
Myocon
Myoglycerin
Myovin
Natispray
Neos nitro OPT
NG
Niglin
Niglycon
Niong
Niong Retard
Nirmin
Nitora
Nitradisc
Nitradisc Pad
Nitradisc TTS
Nitrangin
Nitrek
Nit-Ret
Nitriderm
Nitriderm TTS
Nitrine-TDC
nitro Bid
Nitro Bid
nitro Dur
Nitro Dur
Nitro Dur TTS
NITRO IV
Nitro Mack Retard
Nitro Retard
Nitro Rorer
Nitroard
Nitrobaat
nitro-Bid
NitroBid
Nitro-Bid
Nitro-bid (TN)
Nitrobid Oint
Nitrobukal
Nitrocap
NitrocapT.D
NitrocapT.D.
Nitrocard
Nitrocerin
Nitrocine
Nitrocine 5
Nitroclyn
Nitrocontin
|
Nitrocontin Continus
NitroCor
Nitrocot
Nitroderm
Nitroderm TTS
Nitroderm TTS Ext
Nitroderm TTS-5
Nitrodisc
nitro-Dur
Nitro-dur
NitroDur
Nitro-Dur
Nitro-dur (TN)
Nitro-Dur 10
Nitro-Dur 5
Nitrodyl
Nitrodyl TTS
Nitrogard
Nitrogard-SR
Nitro-Gesanit Retard
Nitroglicerina
Nitrogliceryna
Nitroglin
nitroglycerin
Nitroglycerin
Nitroglycerin (NG)
nitroglycerin ointment
Nitroglycerin ointment
Nitroglycerin-ACC
Nitroglycerine
Nitroglycerol
Nitroglyn
Nitroject
Nitrol
Nitrol Ointment
Nitrolan
Nitro-lent
Nitroletten
Nitrolin
Nitrolingual
Nitrolingual Pump Spray
Nitrolingual Spray
Nitrolowe
Nitromack Retard
Nitro-Mack Retard
Nitro-M-Bid
Nitromed
Nitromel
Nitromex
Nitromint
Nitromint Aerosol
Nitromint Retard
Nitromist
NitroMist
Nitromist (TN)
Nitronal Aqueous
Nitronet
Nitrong
Nitrong parenteral
Nitrong Retard
Nitrong-SR
Nitro-Par
Nitropatch
Nitropen
Nitropercuten
Nitroperlinit
Nitro-Pflaster
Nitroplast
Nitroprol
Nitropront
Nitroprontan
NitroQuick
NitroQuik
Nitrorectal
Nitroretard
Nitrorex
Nitrospan
Nitro-Span
Nitrostabilin
Nitrostat
Nitro-Time
Nitrovis
Nitrozell retard
NK-843
NTG
Nysconitrine
Percutol
Percutol Oint
Percutol Oint.
Perganit
Perglottal
Perlinganit
Plastranit
Polnitrin
Propane-1,2,3-triyl trinitrate
Propane-1,2,3-triyl trinitric acid
Ratiopharm
RCRA waste no. P081
Rectogesic
SDM No. 17
SK-106N
SK-866
SK-878
Soup
Spirit of glonoin
Susadrin
Suscard
Sustac
Sustak
Sustonit
Temponitrin
TNG
Top-Nitro
Transderm nitro
Transderm Nitro
Transderm-N TTS
Transderm-nitro
Transderm-nitro (TN)
Transderm-Nitro TTS
Transiderm-nitro
Tridil
Tridil sublin
Trinalgon
Trinipatch
Triniplas
Trinitrate, glyceryl
Trinitrate, Glyceryl
Trinitrin
Trinitrin Tablets
Trinitrina Erba
Trinitrine
Trinitroglycerin
Trinitroglycerol
Trinitrol
Trinitrolong
Trinitron
Trinitrosan
Turicard
UN0143
UN0144
UN1204
UN3064
UN3319
UNII-G59M7S0WS3
Vascana
Vasoglyn
Vasolator
Vernies
Willong
|
|
10 |
|
Pravastatin |
Approved |
Phase 4 |
|
81093-37-0 |
54687 |
Synonyms:
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoate
(+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid
(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
(3R,5R)-7-[(1S,2S,6S,8S,8AR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid
3beta-Hydroxycompactin
81093-37-0
81131-70-6 (hydrochloride salt)
AC1L1HJL
AC1Q5T3M
apo Pravastatin
apo-Pravastatin
Apotex brand OF pravastatin sodium
Aventis brand OF pravastatin sodium
BIDD:GT0773
BRD-K60511616-236-01-4
Bristacol
Bristol-myers squibb brand OF pravastatin sodium
C01844
C23H36O7
CCRIS 7557
CHEMBL1144
CID54687
Compactin
D08410
DB00175
Elisor
Eptastatin
Esteve brand OF pravastatin sodium
FT-0082682
Juste brand OF pravastatin sodium
KS-5015
Lin pravastatin
Lin-pravastatin
Linson pharma brand OF pravastatin sodium
Lipemol
Liplat
Lipostat
LS-94713
Mevalothin
Mevalotin
Mevastatin
Mevinolin
|
nchembio.301-comp7
nchembio790-comp15
Nu pravastatin
Nu-pharma brand OF pravastatin sodium
Nu-pravastatin
Oliprevin
Prareduct
Pravachol
Pravacol
Pravaselect
Pravasin
pravastatin
Pravastatin
Pravastatin (INN)
Pravastatin [INN:BAN]
Pravastatin acid
Pravastatin monosodium salt, (6 beta)-isomer
Pravastatin sodium
Pravastatin Sodium
Pravastatin sodium salt
Pravastatin Sodium Salt
Pravastatin tert octylamine salt
Pravastatin tert-octylamine salt
Pravastatin tert-Octylamine Salt
Pravastatin, (6 beta)-isomer
Pravastatina
Pravastatina [Spanish]
Pravastatine
Pravastatine [French]
Pravastatinum
Pravastatinum [Latin]
Pravator
Pravator (TN)
RMS 431
RMS-431
sankyo Brand OF pravastatin sodium
Selectin
Selektine
Selipran
Sodium salt, pravastatin
SQ-31,000
Squibb brand OF pravastatin sodium
UNII-KXO2KT9N0G
Vasten
|
|
11 |
|
Acetylsalicylic acid lysinate |
|
Phase 4 |
|
|
|
12 |
|
lysine |
|
Phase 4 |
|
|
|
13 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
14 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
15 |
|
Phosphodiesterase Inhibitors |
|
Phase 4 |
|
|
|
16 |
|
Phosphodiesterase 3 Inhibitors |
|
Phase 4 |
|
|
|
17 |
|
Neuroprotective Agents |
|
Phase 4 |
|
|
|
18 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
19 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
20 |
|
Protective Agents |
|
Phase 4 |
|
|
|
21 |
|
Aspirin, Dipyridamole Drug Combination |
|
Phase 4 |
|
|
|
22 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
23 |
|
Adjuvants, Immunologic |
|
Phase 4 |
|
|
|
24 |
|
interferons |
|
Phase 4 |
|
|
|
25 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
26 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
27 |
|
Radiation-Protective Agents |
|
Phase 4 |
|
|
|
28 |
|
Antiviral Agents |
|
Phase 4 |
|
|
|
29 |
|
calcium heparin |
|
Phase 4 |
|
|
|
30 |
|
Antibiotics, Antitubercular |
|
Phase 4 |
|
|
|
31 |
|
polysaccharide-K |
|
Phase 4 |
|
|
|
32 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 4 |
|
|
|
33 |
|
Lipid Regulating Agents |
|
Phase 4 |
|
|
|
34 |
|
Anticholesteremic Agents |
|
Phase 4 |
|
|
|
35 |
|
Hypolipidemic Agents |
|
Phase 4 |
|
|
|
36 |
|
Antimetabolites |
|
Phase 4 |
|
|
|
37 |
|
Chinese Salvia |
|
Phase 4 |
|
|
|
38 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
39 |
|
Calcium |
Nutraceutical |
Phase 4 |
|
7440-70-2 |
271 |
Synonyms:
Blood coagulation factor XIII
Ca
Ca(2+)
Ca2+
Calcio
Calcium
Calcium element
CALCIUM ion
Calcium, doubly charged positive ion
Calcium, elemental
Coagulation factor XIII
Elemental calcium
Factor XIII
|
Factor XIII a chain
Factor XIII a-chain
Factor XIII transamidase
Factor XIII, coagulation
Fibrin stabilizing factor
Fibrinase
Kalzium
Laki lorand factor
Laki-lorand factor
Stabilizing factor, fibrin
Transamidase, factor XIII
XIII, coagulation factor
|
|
40 |
|
Esomeprazole |
Approved, Investigational |
Phase 3 |
|
161796-78-7, 119141-88-7, 161973-10-0 |
9568614 4594 |
Synonyms:
( -)-Omeprazole
(-)-omeprazole
(−)-omeprazole
(-)-Omeprazole
(-)-Omeprazole magnesium
(S)-(−)-omeprazole
(S)-(-)-Omeprazole
(S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
(S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole
(s)-omeprazole
(S)-omeprazole
(S)-Omeprazole
(S)-Omeprazole magnesium
119141-88-7
119141-89-8
131959-78-9
161973-10-0
172964-80-6
193469-77-1
1H-Benzimidazole, 5-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-, magnesium salt, trihydrate
2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole
2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole
202742-32-3
217087-09-7
302841-07-2
320416-93-1
326602-80-6
371759-50-1
372519-57-8
376628-34-1
5-methoxy-1H-1,3-benzimidazol-2-yl (4-methoxy-3,5-dimethyl-2-pyridinyl)methyl sulfoxide
5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole, magnesium salt (2:1), trihydrate
5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole
5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1-methyl-1H-benzimidazole
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
6-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
73590-58-6
95382-33-5
AC1L1IIJ
AC1L2XM7
AC1L2XMA
AC1NSJYQ
AC-401
AC-402
AGI-010
AKOS005066653
Alenia
Antra
Antra MUPS
AstraZeneca brand OF esomeprazole magnesium
Audazol
AULCER
Axagon
Belmazol
BIDD:GT0020
BIDD:GT0189
Bio-0888
BPBio1_000425
BRD-A55962179-001-04-9
BSPBio_000385
C07324
CAS-73590-58-6
CCRIS 7099
Ceprandal
CHEBI:50275
CHEBI:519601
CHEBI:7772
CHEMBL1503
CID130564
CID130565
CID4594
CID9568613
CID9568614
CID9579578
CPD000058847
D00455
D01984
D05259
D07917
D-961H
Danlox
DB00338
DB00736
Demeprazol
Desec
Dizprazol
DM-3458
Dudencer
Elgam
Emeproton
Emilok
Epirazole
Erbolin
Escz
Esofag
esomeprazol
Esomeprazol
esomeprazole
Esomeprazole
Ésoméprazole
Esomeprazole (INN)
Esomeprazole [INN:BAN]
Esomeprazole magnesium
Esomeprazole magnesium (USAN)
Esomeprazole magnesium hydrate
Esomeprazole magnesium hydrate (JAN)
Esomeprazole magnesium trihydrate
Esomeprazole potassium
Esomeprazole sodium
Esomeprazole Sodium
Esomeprazole strontium
Esomeprazole strontium anhydrous
esomeprazolum
Esomeprazolum
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168/68
H 168-68
H 199/18
H168/68
H-168/68
H199/18
H-199/18
HMS1528I05
HMS1569D07
HMS2052G17
HMS2090E16
HMS2090F11
HSDB 3575
I06-0705
I06-1976
IDI1_032523
InChI=1/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20
Indurgan
|
Inexium paranova
Inexium paranova (TN)
Inhibitron
Inhipump
KS-1054
Lensor
Logastric
Lomac
Losec
Losec, Omesec, Prilosec, Zegerid, Omeprazole
LS-181810
LS-185188
LS-7629
Lucen
magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide
magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide trihydrate
Maybridge4_002645
Mepral
Miol
Miracid
MLS000069373
MLS001076112
MLS001165732
MLS001424148
MolPort-002-885-822
MolPort-003-666-741
MolPort-003-807-515
MolPort-003-849-702
MolPort-005-940-841
MolPort-005-943-880
Mopral
Morecon
N Bis (1H-Benzimidazole,5-methoxy-2-[(S)-[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl]-)
NCGC00016925-01
NCGC00016925-02
NCGC00021522-03
NCGC00021522-04
NCGC00021522-05
Nexiam
Nexium
Nexium (TN)
Nexium Control
Nexium IV
Nexium, Esomeprazole magnesium
Nilsec
Nopramin
Nuclosina
O0359
O104_SIGMA
Ocid
Olexin
Olit
Omapren
Omebeta
Omebeta 20
Omed
Omegast
OMEP
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
omeprazole
Omeprazole (JAN/USP/INN)
Omeprazole [USAN:INN:BAN:JAN]
Omeprazole delayed-release
Omeprazole magnesium
Omeprazole S-form
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprazone
Omeprol
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
Ompanyt
OMZ
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Perprazole
Prazentol
Prazidec
Prazolit
Prestwick_808
Prestwick0_000493
Prestwick1_000493
Prestwick2_000493
Prestwick3_000493
Prilosec
Prilosec (TN)
Prilosec OTC
Prilosec OTC (TN)
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
S1389_Selleck
S1743_Selleck
SAM001246900
SAN-15
Sanamidol
Secrepina
SMR000058847
SMR000550477
SPBio_002306
ST51053319
STK623746
Strontium, esomeprazole
Tedec Ulceral
TL8005099
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
UNII-KG60484QX9
UNII-N3PA6559FT
UNII-R6DXU4WAY9
UPCMLD-DP075
UPCMLD-DP075:001
Victrix
Zefxon
Zegerid
Zepral
Zimor
ZINC04693574
ZINC04693575
Zoltum
|
|
41 |
|
Hemostatics |
|
Phase 3 |
|
|
|
42 |
|
Gastrointestinal Agents |
|
Phase 3 |
|
|
|
43 |
|
Antacids |
|
Phase 3 |
|
|
|
44 |
|
Anti-Ulcer Agents |
|
Phase 3 |
|
|
|
45 |
|
Proton Pump Inhibitors |
|
Phase 3 |
|
|
|
46 |
|
Omega 3 Fatty Acid |
|
Phase 1, Phase 2 |
|
|
|
47 |
|
Meloxicam |
Approved, Vet_approved |
Phase 1 |
|
71125-38-7 |
54677470 5281106 |
Synonyms:
(3E)-3-[hydroxy-[(5-methyl-1,3-thiazol-2-yl)amino]methylidene]-2-methyl-1,1-dioxo-1
133687-22-6
2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methylthiazolyl)-, 1,1-dioxide
4-hydroxy-2-mehtyl-N-(5-mehtyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
4-Hydroxy-2-methyl-N-(5-methyl-2-thiazoyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
71125-38-7
Abbott brand of meloxicam
AC-1325
AC1NQY12
AC1Q3XZW
AKOS000279442
Almirall brand of meloxicam
Apo-meloxicam
Bio-0826
Boehringer Ingelheim brand of meloxicam
C065757
C08169
C14H13N3O4S2
CCRIS 9139
CHEMBL599
CID5281106
Co Meloxicam
D00969
DB00814
Dom-meloxicam
Europharma brand of meloxicam
FT-0082769
Gen-meloxicam
HMS1922D19
HMS2089B18
I06-0490
LS-40538
M1959
Masflex
meloxicam
|
Meloxicam
Méloxicam
Meloxicam (JAN/USAN/INN)
Meloxicam [USAN:BAN:INN]
Meloxicamum
Meloxicamum [latin]
Meloxicamum [Latin]
Meloxivet
Metacam
miloxicam
Miloxicam
Mobec
Mobic
Mobic (TN)
Mobic, Metacam, Parocin, Meloxicam
Mobicox
MolPort-002-885-839
Movalis
Movatec
Movicox
Novo-meloxicam
Parocin
PHL-meloxicam
PMS-meloxicam
Promeco brand of meloxicam
Ratio-meloxicam
reumoxicam
Reumoxicam
S1734_Selleck
SPECTRUM1504150
Squibb brand of meloxicam
STK620505
Tenaron
TL8005001
UH-AC 62XX
UHAC-62XX
UNII-VG2QF83CGL
Uticox
|
|
48 |
|
Cyclooxygenase 2 Inhibitors |
|
Phase 1 |
|
|
|
49 |
|
Simvastatin |
Approved |
|
|
79902-63-9 |
54454 |
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
2,2-Dimethylbutyrate, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
79902-63-9
AC-1530
AC1L1H1F
AKOS005111006
ARONIS24119
BCBcMAP01_000007
BIDD:GT0769
Bio-0672
BPBio1_001001
BRD-K22134346-001-05-8
BRN 4768037
BSPBio_000909
BSPBio_002337
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta
C25H38O5
CCRIS 7558
CHEBI:9150
CHEMBL1064
Cholestat
CID54454
Coledis
Colemin
Corolin
CPD000718785
D00434
D019821
Denan
DivK1c_006991
DRG-0320
Eucor
HMS1570N11
HMS1922H13
HMS2089D12
HMS2093E06
HSDB 7208
InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
KBio1_001935
KBio2_002197
KBio2_004765
KBio2_007333
KBio3_001557
KBioGR_001244
KBioSS_002197
Kolestevan
KS-1113
L 644128-000U
Labistatin
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
LS-46264
Medipo
MK 0733
MK 733
MK-0733
MK733
MK-733
|
MLS001304029
MLS001333077
MLS001333078
MLS002154038
Modutrol
MolPort-002-507-345
MolPort-002-885-862
NCGC00017324-01
NCGC00017324-02
NCGC00017324-03
nchembio790-comp16
Nivelipol
Nor-vastina
Pantok
Pepstatin
Prestwick_171
Prestwick0_000865
Prestwick1_000865
Prestwick2_000865
Prestwick3_000865
Rechol
Rendapid
S1792_Selleck
S6196_SIGMA
SAM002589969
Simcor
Simovil
Simvast CR
simvastatin
Simvastatin
Simvastatin & Primycin
Simvastatin (JAN/USP/INN)
Simvastatin [Usan:Ban:Inn]
Simvastatin [USAN:INN:BAN]
Simvastatin lactone
Simvastatin, Compactin
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
Sivastin
SMR000718785
SPBio_001881
SPBio_002830
SpecPlus_000895
Spectrum_001717
SPECTRUM1504236
Spectrum2_001671
Spectrum3_000669
Spectrum4_000632
Spectrum5_001428
Statin
STK801938
Synvinolin
TNP00259
UNII-AGG2FN16EV
Valemia
Vasotenal
Velostatin
Vytorin
ZINC03780893
Zocor
Zocor (TN)
Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin
Zocord
|
|
50 |
|
Nutmeg |
Approved |
|
|
|
|
Interventional clinical trials:
(show top 50)
(show all 65)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Impact of Different Pharmacological Formulations on Aspirin Resistance Reversibility in Diabetics Patients |
Unknown status |
NCT01935193 |
Phase 4 |
lysine acetylsalicylate |
2 |
a Comparative Study of Aspirin Either at Fixed Dose or at a Dose Titrated by Platlet Function Analyzer(PFA-100) vs Placebo in Primary Prevention of Vascular Access for Hemodialysis |
Unknown status |
NCT02055131 |
Phase 4 |
aspirin |
3 |
Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients |
Unknown status |
NCT02933788 |
Phase 4 |
Cilostazol;Acetylsalicylic acid |
4 |
Validation of the Clinical Applicability of Various Platelet Function Assessments in High-Risk Atherothrombotic Patients Undergoing Percutaneous Coronary Angioplasty: Phase 4 Study |
Unknown status |
NCT00513149 |
Phase 4 |
Clopidogrel |
5 |
Phase 4 Study of Additional Cilostazol for Overcoming Biochemical Aspirin Resistance in the Chronic Stroke Patients |
Completed |
NCT00446641 |
Phase 4 |
Cilostazol;placebo |
6 |
Aspirin Responsiveness in Women at Risk for Cardiac Events: A Pilot Study. |
Completed |
NCT00818337 |
Phase 4 |
Aspirin |
7 |
A Randomised, Crossover Study Comparing the Biochemical and Platelet Effects of Modified-release Dipyridamole/Aspirin (200mg/25 mg bd; Asasantin Retard®) With Aspirin (75 mg qd) in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation. |
Completed |
NCT00129038 |
Phase 4 |
modified-release dipyridamole/aspirin;aspirin |
8 |
Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting |
Completed |
NCT01159639 |
Phase 4 |
Clopidogrel |
9 |
Aspirin Non-responsiveness and Clopidogrel Endpoint Trial. |
Completed |
NCT00222261 |
Phase 4 |
aspirin;clopidogrel |
10 |
Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel |
Completed |
NCT00398463 |
Phase 4 |
Tirofiban;Placebo |
11 |
Prevalence of Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Prognostic Significance of Resistance to Aspirin |
Completed |
NCT00262561 |
Phase 4 |
Aspirin |
12 |
Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events |
Completed |
NCT02616497 |
Phase 4 |
Aspirin;Triflusal |
13 |
Aspirin Statins Or Both For The Reduction Of Thrombin Generation In Diabetic People |
Completed |
NCT00793754 |
Phase 4 |
Aspirin;Atorvastatin;Aspirin + Atorvastatin |
14 |
Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index With Stable Angina Pectoris of Coronary Heart Disease as an Example |
Completed |
NCT01502943 |
Phase 4 |
Louxiangdan Tongxin granules;TCM granules placebo;Chixiangshen Tongxin granules;TCM granule placebo plus western basis treatment;Western basis treatment |
15 |
The Effect of 81mg vs 162mg ASA for Preeclampsia Prevention in Obese Women at High Risk for Developing Preeclampsia |
Recruiting |
NCT03735433 |
Phase 4 |
162mg aspirin dose |
16 |
Efficacy of Monitoring of Aspirin Responsiveness in the Prevention of Cardiovascular Events and Decrease in Bleeding Complications in Patients With End-Stage Kidney Disease Undergoing Hemodialysis |
Withdrawn |
NCT01198379 |
Phase 4 |
aspirin;Placebo |
17 |
Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents |
Withdrawn |
NCT00589862 |
Phase 4 |
Plavix (Clopidogrel) |
18 |
Methods to Augment the Efficacy of Aspirin and Clopidogrel in Healthy Subjects (ASA Only) and Patients With Stable Coronary Artery Disease (Taking Clopidogrel Only) or (Taking Clopidogrel & ASA) With an Elevated Platelet Turnover (Reticulated Platelets). |
Withdrawn |
NCT01011257 |
Phase 4 |
Asprin;Clopidogrel |
19 |
ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery(TEG-CABG Trial):Does Intensified Postoperative Antiplatelet Therapy in Preoperatively Identified Hypercoagulable Patients Improve Outcome After CABG Surgery |
Unknown status |
NCT01046942 |
Phase 3 |
Clopidogrel+acetylsalicylic acid;acetylsalicylic acid |
20 |
Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance in The Patients Treated With Primary PCI for STEMI |
Unknown status |
NCT00697021 |
Phase 3 |
Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG;Aspirin 100mg and Plavix 75mg |
21 |
A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia |
Unknown status |
NCT00357682 |
Phase 3 |
Esomeprazole;Esomeprazole;Aspirin |
22 |
Pilot Study of Preoperative Aspirin and Postoperative Clopidogrel's Effects on Graft Patency and Cardiac Events in Coronary Artery Bypass Surgery |
Completed |
NCT00330772 |
Phase 3 |
Aspirin;Clopidogrel |
23 |
Multiple Daily Doses of Aspirin to Overcome Hyporesponsiveness Post Cardiac Bypass Surgery (ASACABG)- Part B |
Completed |
NCT01902498 |
Phase 2 |
Aspirin;Aspirin;Aspirin |
24 |
The Effects of Omega-3 Fatty Acids on Aspirin Resistance |
Completed |
NCT00771914 |
Phase 1, Phase 2 |
Aspirin;Lovaza;Both Aspirin and Lovaza |
25 |
Multiple Daily Doses Of Aspirin To Overcome Aspirin Hyporesponsiveness Post Cardiac Bypass Surgery |
Completed |
NCT01618006 |
Phase 2 |
Aspirin;Aspirin;Aspirin |
26 |
The Effects of Fish Oil and Aspirin on Cardiovascular Risk in Type 2 Diabetes |
Completed |
NCT01181882 |
Phase 2 |
|
27 |
ASpirin as a Treatment for ARDS (STAR): a Phase 2 Randomised Control Trial |
Terminated |
NCT02326350 |
Phase 2 |
Aspirin 75mg;Lactose powder |
28 |
Bleeding Volume Test: A Double-Blind Crossover Randomized Clinical Trial of an In-Vivo On-Line Test for Aspirin Effect and Resistance |
Unknown status |
NCT01047722 |
Phase 1 |
Aspirin ingestion followed by doing a Bleeding Volume Test |
29 |
Mechanism Based Resistance to Aspirin |
Completed |
NCT00948987 |
Phase 1 |
Aspirin |
30 |
Vascular Damage in Systemic Lupus Erythematosus (SLE) |
Completed |
NCT00731302 |
Phase 1 |
aspirin and meloxicam |
31 |
Phase 1 Study to Assess the Safety of 500mg of Aspirin Added to IV TPA at Standard Doses to Prevent Re-occlusion of Cerebral Vessels After Successful Reperfusion. |
Withdrawn |
NCT00417898 |
Phase 1 |
Aspirin |
32 |
Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient |
Unknown status |
NCT01045785 |
|
|
33 |
Prevalence and Level of Thienopyridine Resistance Seen in a Contemporary PCI and CABG Population |
Unknown status |
NCT01408927 |
|
|
34 |
Is There A LIfe for DES After Discontinuation of Clopidogrel:The ITALIC PLUS Trial |
Unknown status |
NCT01476020 |
|
|
35 |
Thrombin Dysregulation Leads to Early Saphenous Vein Graft Failure |
Unknown status |
NCT00481806 |
|
|
36 |
Effects of Prescription OMega-3 Fatty Acids (Omacor®, Lovaza®) on Platelet Activity in Patients With Coronary Artery Disease With Hypertriglyceridemia (OMPA-CAD) |
Unknown status |
NCT01086163 |
|
Omacor, omega-3 fatty acids in CAD patients |
37 |
Prevalence of Aspirin Resistance in Hemodialysis Patients |
Completed |
NCT00792272 |
|
|
38 |
Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients |
Completed |
NCT01364779 |
|
|
39 |
Genotypic and Phenotypic Correlates of Resistance to Anti-platelet Actions of Aspirin in an At-risk Patient Population and in the General Population |
Completed |
NCT01361620 |
|
aspirin |
40 |
Cardiovascular Events at One Year of Patients Hospitalized for Critical Limb Ischaemia and Aspirin Resistant Using the VerifyNow®. Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia |
Completed |
NCT01104441 |
|
|
41 |
Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients |
Completed |
NCT00649909 |
|
|
42 |
Aspirin Responsiveness in Women With Coronary Artery Disease |
Completed |
NCT01406990 |
|
|
43 |
Comparative Evaluation of Aspirin Resistance With Point-of-Care Testing - Danish Aspirin Resistance Trial (DANART) - Pilot Study |
Completed |
NCT00389129 |
|
acetylsalicylic acid |
44 |
Evaluation of Aspirin Resistance at a Molecular Level in Aspirin-Treated Patients With Coronary Artery Disease |
Completed |
NCT00753935 |
Early Phase 1 |
enteric-coated aspirin;Chewable aspirin |
45 |
Laboratory Aspirin Resistance in Coronary Artery Disease Patients With or Without Diabetes Mellitus |
Completed |
NCT00563875 |
|
acetylsalicylic acid |
46 |
Optimum Platelet Inhibition After Coronary Artery Bypass Surgery: A Randomised Trial Comparing Platelet Aggregation Using Low, Medium Dose Aspirin and Clopidogrel |
Completed |
NCT00262275 |
|
Aspirin, Clopidogrel |
47 |
The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study)-A Prospective Multicenter Cohort Study- |
Completed |
NCT00250380 |
|
|
48 |
Aspirin Resistance in Obstructive Sleep Apnea Patients (ARISA Trial) |
Completed |
NCT03930875 |
|
|
49 |
The Effect of Serum LDL Lowering on Aspirin Resistance |
Completed |
NCT00466154 |
|
Aspirin |
50 |
Efficacité du Traitement antiagrégant Par Acide acétylsalicylique en Chirurgie Vasculaire mesurée Par agrégométrie Par impédance |
Completed |
NCT01432652 |
|
|
|